TRVI Stock Forecast & Price Target

Trevi Therapeutics Inc has demonstrated strong operational progress with its investigational therapy Haduvio, successfully advancing toward Phase 3 development for chronic cough related to idiopathic pulmonary fibrosis, supported by a robust cash position of $194.9 million that is expected to sustain operations through 2028. The company has also reported a narrowing net loss to $11.8 million compared to $13.2 million the previous year, indicating improved financial efficiency while expanding its corporate and professional activities in preparation for late-stage development. With forecasts estimating a sales opportunity of around $1.5 billion for Haduvio in IPF chronic cough and an additional potential of approximately $3 billion in refractory chronic cough, there is significant upside potential as clinical data presentations continue to improve market prospects.

Trevi Therapeutics Inc. faces substantial financial challenges due to the high costs associated with R&D, which totaled $10.1 million in Q3 and reflects a reduction from the previous year primarily due to the discontinuation of earlier clinical trials. The company is confronted with significant risks, including potential delays in Haduvio's development and competition from other therapeutics, which could adversely impact its commercialization efforts and overall market position. Additionally, Trevi may need to secure additional financing as it approaches profitability, compounding the volatility and uncertain outlook surrounding its share price.